CEO COMMENTS
Gunnar Olsson comments Q1 report 2024
“On May 7 we announced that we signed an agreement to start a development collaboration for IRL757 with MSRD, a company within the Otsuka group. Within the framework of the agreement, together we will develop the substance to completed clinical Proof-of-Concept. The patient studies will include people with both Parkinson’s and Alzheimer’s disease. Through the collaboration agreement, IRLAB receives USD 3 million upon signing and additional activity based milestones of USD 5.5 million. In addition, MSRD/Otsuka will cover all cost for the full development program, i.a. CMC development, toxicology studies and the clinical studies.”
LATEST REPORTS
IRLAB publishes interim report for the period January-June 2024
Gothenburg, Sweden, July 10, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-June 2024, has been publihed.
Read More >
Fireside chat with Viktor Siewertz, CFO, at ABGSC
Viktor Siewertz, CFO, participated in the ABGSC fireside chat, moderated by Alexander Krämer, analyst at ABGSC, The event was recorded on March 5 and published on March 7, 2024.
Read More >FINANCIAL CALENDAR
NEXT
July 10, 2024
Interim Report January – June 2024